Safety of treatments for primary Sjögrens syndrome

Expert Opinion on Drug Safety

Volumn 15, Issue 4, 2016, Pages 513-524

  Van Nimwegen, Jolien F ^a   Moerman, Rada V ^a   Sillevis Smitt, Nicole ^a   Brouwer, Elisabeth ^a   Bootsma, Hendrika ^a   Vissink, Arjan ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

biologic DMARDs; drug safety; Primary Sj gren's syndrome; synthetic DMARDs; topical treatment

Indexed keywords

ABATACEPT; ARTIFICIAL TEAR; AZATHIOPRINE; BAMINERCEPT; BELIMUMAB; CEVIMELINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DISEASE MODIFYING ANTIRHEUMATIC DRUG; EPRATUZUMAB; FLUORIDE; GLUCOCORTICOID; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN G; MYCOPHENOLATE MOFETIL; NONSTEROID ANTIINFLAMMATORY AGENT; PILOCARPINE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; ANTIRHEUMATIC AGENT; IMMUNOSUPPRESSIVE AGENT;

DISEASE ACTIVITY; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MECHANICAL STIMULATION; MOUTH DISEASE; OUTCOME ASSESSMENT; PALLIATIVE THERAPY; PERSONAL HYGIENE; REVIEW; SJOEGREN SYNDROME; SUBSTITUTION THERAPY; SYSTEMIC THERAPY; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; SAFETY; SJOGREN'S SYNDROME;

ANTIRHEUMATIC AGENTS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; SAFETY; SJOGREN'S SYNDROME;

EID: 84958568714     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2016.1146676     Document Type: Review

References (132)

1. Kroese FGM, Abdulahad WH, Haacke E, et al. B-cell hyperactivity in primary Sjögren's syndrome. Expert Rev Clin Immunol. 2014;10:483-499.
2. Meijer JM, Meiners PM, Huddleston Slater JJ, et al. Health-related quality of life, employment and disability in patients with Sjogren's syndrome. Rheumatology (Oxford). 2009;48:1077-1082.
3. Verstappen GM, Kroese FG, Vissink A, et al. Pharmacotherapy for managing extraglandular symptoms of primary Sjögren's syndrome. Expert Opin Orphan Drugs. 2015;3:125-139.
4. Pijpe J, Kalk WWI, Bootsma H, et al. Progression of salivary gland dysfunction in patients with Sjogren's syndrome. Ann Rheum Dis. 2006;66:107-112.
5. Stevens RJ. Flares of systemic disease in primary Sjogren's syndrome. Rheumatology. 2005;44:402-403.
6. Ramos-Casals M, Solans R, Rosas J, et al. Primary Sjögren syndrome in Spain. Medicine (Baltimore). 2008;87:210-219.
7. Seror R, Gottenberg JE, Devauchelle-Pensec V, et al. European League against Rheumatism Sjögren's syndrome disease activity index and European League against Rheumatism Sjögren's syndrome patient-reported index: A complete picture of primary Sjögren's syndrome patients. Arthritis Care Res (Hoboken). 2013;65:1358-1364.
8. Seror R, Bootsma H, Saraux A, et al. Defining disease activity states and clinically meaningful improvement in primary Sjögren's syndrome with EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI). Ann Rheum Dis. 2016;75:382-389.
9. Ciurtin C, Ostas A, Cojocaru VM, et al. Advances in the treatment of ocular dryness associated with Sjögren s syndrome. Semin Arthritis Rheum. 2015;45:321-327.
10. Moshirfar M, Pierson K, Hanamaikai K, et al. Artificial tears potpourri: A literature review. Clin Ophthalmol. 2014;8:1419-1433.
11. Furrer P, Mayer JM, Gurny R. Ocular tolerance of preservatives and alternatives. Eur J Pharm Biopharm. 2002;53:263-280.
12. Charnock C. Are multidose over-The-counter artificial tears adequately preserved? Cornea. 2006;25:432-437.
13. Matsumoto Y, Dogru M, Goto E, et al. Autologous serum application in the treatment of neurotrophic keratopathy. Ophthalmology. 2004;111:1115-1120.
14. Tananuvat N, Daniell M, Sullivan LJ, et al. Controlled study of the use of autologous serum in dry eye patients. Cornea. 2001;20:802-806.
15. Tsubota K, Goto E, Fujita H, et al. Treatment of dry eye by autologous serum application in Sjögren's syndrome. Br J Ophthalmol. 1999;83:390-395.
16. Ogawa Y, Okamoto S, Mori T, et al. Autologous serum eye drops for the treatment of severe dry eye in patients with chronic graft-versushost disease. Bone Marrow Transplant. 2003;31:579-583.
17. Rocha EM, Pelegrino FS, de Paiva CS, et al. GVHD dry eyes treated with autologous serum tears. Bone Marrow Transplant. 2000;25:1101-1103.
18. Pflugfelder SC, De Paiva CS, Villarreal AL, et al. Effects of sequential artificial tear and cyclosporine emulsion therapy on conjunctival goblet cell density and transforming growth factor-β2 production. Cornea. 2008;27:64-69.
19. Kunert KS, Tisdale AS, Gipson IK. Goblet cell numbers and epithelial proliferation in the conjunctiva of patients with dry eye syndrome treated with cyclosporine. Arch Ophthalmol. 2002;120:330-337.
20. Kunert KS, Tisdale AS, Stern ME, et al. Analysis of topical cyclosporine treatment of patients with dry eye syndrome: effect on conjunctival lymphocytes. Arch Ophthalmol. 2000;118:1489-1496.
21. Demiryay E, Yaylali V, Cetin EN, et al. Effects of topical cyclosporine a plus artificial tears versus artificial tears treatment on conjunctival goblet cell density in dysfunctional tear syndrome. Eye Contact Lens. 2011;37:312-315.
22. Behrens A, Doyle JJ, Stern L, et al. Dysfunctional tear syndrome: A Delphi approach to treatment recommendations. Cornea. 2006;25:900-907.
23. Barber LD, Pflugfelder SC, Tauber J, et al. Phase III safety evaluation of cyclosporine 0.1% ophthalmic emulsion administered twice daily to dry eye disease patients for up to 3 years. Ophthalmology. 2005;112:1790-1794.
24. Fakhraie G, Lopes JF, Spaeth GL, et al. Effects of postoperative cyclosporine ophthalmic emulsion 0.05% (Restasis) following glaucoma surgery. Clin Experiment Ophthalmol. 2009;37:842-848.
25. Dursun D, Kim MC, Solomon A, et al. Treatment of recalcitrant recurrent corneal erosions with inhibitors of matrix metalloproteinase-9, doxycycline and corticosteroids. Am J Ophthalmol. 2001;132:8-13.
26. Lin T, Gong L. Topical fluorometholone treatment for ocular dryness in patients with Sjögren syndrome: A randomized clinical trial in China. Medicine (Baltimore). 2015;94:e551.
27. Aragona P, Spinella R, Rania L, et al. Safety and efficacy of 0.1% clobetasone butyrate eyedrops in the treatment of dry eye in Sjögren syndrome. Eur J Ophthalmol. 2013;23:368-376.
28. Pflugfelder SC, Maskin SL, Anderson B, et al. A randomized, doublemasked, placebo-controlled, multicenter comparison of loteprednol etabonate ophthalmic suspension, 0.5%, and placebo for treatment of keratoconjunctivitis sicca in patients with delayed tear clearance. Am J Ophthalmol. 2004;138:444-457.
29. Lemp MA. Management of dry eye disease. Am J Manag Care. 2008;14:S88-101.
30. Aragona P, Stilo A, Ferreri F, et al. Effects of the topical treatment with NSAIDs on corneal sensitivity and ocular surface of Sjögren's syndrome patients. Eye (Lond). 2005;19:535-539.
31. Avisar R, Robinson A, Appel I, et al. Diclofenac sodium, 0.1% (Voltaren Ophtha), versus sodium chloride, 5%, in the treatment of filamentary keratitis. Cornea. 2000;19:145-147.
32. Avunduk AM, Avunduk MC, Varnell ED, et al. The comparison of efficacies of topical corticosteroids and nonsteroidal anti-inflammatory drops on dry eye patients: A clinical and immunocytochemical study. Am J Ophthalmol. 2003;136:593-602.
33. Guidera AC, Luchs JI, Udell IJ. Keratitis, ulceration, and perforation associated with topical nonsteroidal anti-inflammatory drugs. Ophthalmology. 2001;108:936-944.
34. Hsu JKW, Johnston WT, Read RW, et al. Histopathology of corneal melting associated with diclofenac use after refractive surgery. J Cataract Refract Surg. 2003;29:250-256.
35. Sreebny LM, Vissink A. Dry mouth, the malevolent symptom: A clinical guide. Ames: Wiley-Blackwell; 2010.
36. Regelink G, Vissink A, Reintsema H, et al. Efficacy of a synthetic polymer saliva substitute in reducing oral complaints of patients suffering from irradiation-induced xerostomia. Quintessence Int. 1998;29:383-388.
37. Kielbassa AM, HinkelbeinW, Hellwig E, et al. Radiation-related damage to dentition. Lancet Oncol. 2006;7:326-335.
38. Jansma J, Vissink A, Bouma J, et al. A survey of prevention and treatment regimens for oral sequelae resulting from head and neck radiotherapy used in Dutch radiotherapy institutes. Int J Radiat Oncol Biol Phys. 1992;24:359-367.
39. Marinho VCC, Higgins JPT, Logan S, et al. Topical fluoride (toothpastes, mouthrinses, gels or varnishes) for preventing dental caries in children and adolescents. Cochrane Database Syst Rev. 2003;(4): CD002782. http://www.ncbi.nlm.nih.gov/pubmed/14583954
40. Fox RI, Konttinen Y, Fisher A. Use of muscarinic agonists in the treatment of Sjögren's syndrome. Clin Immunol. 2001;101:249-263.
41. Vivino FB, Al-Hashimi I, Khan Z, et al. Pilocarpine tablets for the treatment of dry mouth and dry eye symptoms in patients with Sjogren syndrome: A randomized, placebo-controlled, fixed-dose, multicenter trial. P92-01 Study Group. Arch Intern Med. 1999;159:174-181.
42. Papas AS, Sherrer YS, Charney M, et al. Successful treatment of dry mouth and dry eye symptoms in Sjogren's syndrome patients with oral pilocarpine: A randomized, placebo-controlled, dose-adjustment study. J Clin Rheumatol. 2004;10:169-177.
43. Wu C-H, Hsieh S-C, Lee K-L, et al. Pilocarpine hydrochloride for the treatment of xerostomia in patients with Sjögren's syndrome in Taiwan-A double-blind, placebo-controlled trial. J Formos Med Assoc. 2006;105:796-803.
44. Tsifetaki N, Kitsos G, Paschides CA, et al. Oral pilocarpine for the treatment of ocular symptoms in patients with Sjögren's syndrome: A randomised 12 week controlled study. Ann Rheum Dis. 2003;62:1204-1207.
45. Kawakita T, Shimmura S, Tsubota K. Effect of oral pilocarpine in treating severe dry eye in patients with Sjögren syndrome. Asia-Pacific J Ophthalmol (Philadelphia, Pa). 2015;4:101-105.
46. Tomiita M, Takei S, Kuwada N, et al. Efficacy and safety of orally administered pilocarpine hydrochloride for patients with juvenileonset Sjögren's syndrome. Mod Rheumatol. 2010;20:486-490.
47. Suzuki K, Matsumoto M, Nakashima M, et al. Effect of cevimeline on salivary components in patients with Sjögren syndrome. Pharmacology. 2005;74:100-105.
48. Leung KCM, McMillan AS, Wong MCM, et al. The efficacy of cevimeline hydrochloride in the treatment of xerostomia in Sjögren's syndrome in southern Chinese patients: A randomised double-blind, placebocontrolled crossover study. Clin Rheumatol. 2008;27:429-436.
49. Yamada H, Nakagawa Y, Wakamatsu E, et al. Efficacy prediction of cevimeline in patients with Sjögren's syndrome. Clin Rheumatol. 2007;26:1320-1327.
50. Ono M, Takamura E, Shinozaki K, et al. Therapeutic effect of cevimeline on dry eye in patients with Sjögren's syndrome: A randomized, double-blind clinical study. Am J Ophthalmol. 2004;138:6-17.
51. Fife RS, Chase WF, Dore RK, et al. Cevimeline for the treatment of xerostomia in patients with Sjögren syndrome: A randomized trial. Arch Intern Med. 2002;162:1293-1300.
52. Petrone D, Condemi JJ, Fife R, et al. A double-blind, randomized, placebo-controlled study of cevimeline in Sjögren's syndrome patients with xerostomia and keratoconjunctivitis sicca. Arthritis Rheum. 2002;46:748-754.
53. Noaiseh G, Baker JF, Vivino FB. Comparison of the discontinuation rates and side-effect profiles of pilocarpine and cevimeline for xerostomia in primary Sjögren's syndrome. Clin Exp Rheumatol. 2014;32:575-577.
54. Ramos-Casals M, Brito-Zerón P, Sisó-Almirall A, et al. Topical and systemic medications for the treatment of primary Sjögren's syndrome. Nat Rev Rheumatol. 2012;8:399-411.
55. Selmi C, Ceribelli A, Naguwa SM, et al. Safety issues and concerns of new immunomodulators in rheumatology. Expert Opin Drug Saf. 2015;14:389-399.
56. Ramiro S, Gaujoux-Viala C, Nam JL, et al. Safety of synthetic and biological DMARDs: A systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis. 2014;73:529-535.
57. Skopouli FN, Jagiello P, Tsifetaki N, et al. Methotrexate in primary Sjögren's syndrome. Clin Exp Rheumatol. 1996;14:555-558.
58. Van Woerkom JM, Kruize AA, Geenen R, et al. Safety and efficacy of leflunomide in primary Sjogren's syndrome: A phase II pilot study. Ann Rheum Dis. 2007;66:1026-1032.
59. Price EJ, Rigby SP, Clancy U, et al. A double blind placebo controlled trial of azathioprine in the treatment of primary Sjögren's syndrome. J Rheumatol. 1998;25:896-899.
60. Willeke P, Schlüter B, Becker H, et al. Mycophenolate sodium treatment in patients with primary Sjögren syndrome: A pilot trial. Arthritis Res Ther. 2007;9:R115.
61. Drosos AA, Skopouli FN, Galanopoulou VK, et al. Cyclosporin a therapy in patients with primary Sjögren's syndrome: results at one year. Scand J Rheumatol Suppl. 1986;61:246-249.
62. Xiong W, Lahita RG. Pragmatic approaches to therapy for systemic lupus erythematosus. Nat Rev Rheumatol. 2014;10:97-107.
63. Migkos MP, Markatseli TE, Iliou C, et al. Effect of hydroxychloroquine on the lipid profile of patients with Sjögren syndrome. J Rheumatol. 2014;41:902-908.
64. Maria NI, Brkic Z, Waris M, et al. MxA as a clinically applicable biomarker for identifying systemic interferon type I in primary Sjogren's syndrome. Ann Rheum Dis. 2014;73:1052-1059.
65. Gottenberg J-E, Ravaud P, Puéchal X, et al. Effects of hydroxychloroquine on symptomatic improvement in primary Sjögren syndrome. JAMA. 2014;312:249.
66. Kruize AA, Hene RJ, Kallenberg CG, et al. Hydroxychloroquine treatment for primary Sjogren's syndrome: A two year double blind crossover trial. Ann Rheum Dis. 1993;52:360-364.
67. Marmor MF, Kellner U, Lai TYY, et al. Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy. Ophthalmology. 2011;118: 415-422.
68. Costedoat-Chalumeau N, Hulot J-S, Amoura Z, et al. Heart conduction disorders related to antimalarials toxicity: an analysis of electrocardiograms in 85 patients treated with hydroxychloroquine for connective tissue diseases. Rheumatology. 2007;46:808-810.
69. Bortoli R, Santiago M. Chloroquine ototoxicity. Clin Rheumatol. 2007;26:1809-1810.
70. Kwon J-B, Kleiner A, Ishida K, et al. Hydroxychloroquine-induced myopathy. J Clin Rheumatol. 2010;16:28-31.
71. Costedoat-Chalumeau N, Amoura Z, Huong DLT, et al. Safety of hydroxychloroquine in pregnant patients with connective tissue diseases. Review of the literature. Autoimmun Rev. 2005;4:111-115.
72. Motta M, Tincani A, Faden D, et al. Follow-up of infants exposed to hydroxychloroquine given to mothers during pregnancy and lactation. J Perinatol. 2005;25:86-89.
73. Pijpe J, Kalk WW, Bootsma H, et al. Progression of salivary gland dysfunction in patients with Sjogren's syndrome. Ann Rheum Dis. 2007;66:107-112.
74. Marder W, McCune WJ. Advances in immunosuppressive therapy. Semin Respir Crit Care Med. 2007;28:398-417.
75. Yilmaz N, Emmungil H, Gucenmez S, et al. Incidence of cyclophosphamide-induced urotoxicity and protective effect of mesna in rheumatic diseases. J Rheumatol. 2015;42:1661-1666.
76. Deheinzelin D, Capelozzi VL, Kairalla RA, et al. Interstitial lung disease in primary Sjögren's syndrome. Clinical-pathological evaluation and response to treatment. Am J Respir Crit Care Med. 1996;154:794-799.
77. Swann PF, Waters TR, Moulton DC, et al. Role of postreplicative DNA mismatch repair in the cytotoxic action of thioguanine. Science. 1996;273:1109-1111.
78. Fischer A, Brown KK, Du Bois RM, et al. Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease. J Rheumatol. 2013;40:640-646.
79. Rubbert-Roth A. Assessing the safety of biologic agents in patients with rheumatoid arthritis. Rheumatology (Oxford). 2012;51(Suppl 5): v38-47.
80. Singh JA, Cameron C, Noorbaloochi S, et al. Risk of serious infection in biological treatment of patients with rheumatoid arthritis: A systematic review and meta-analysis. Lancet. 2015;386:258-265.
81. van Assen S, Agmon-Levin N, Elkayam O, et al. EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2011;70:414-422.
82. Singh JA, Furst DE, Bharat A, et al. update of the 2008 American College of Rheumatology recommendations for the use of diseasemodifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2012;2012 (64):625-639.
83. Voulgarelis M. Long term remission of Sjogren's syndrome associated aggressive B cell non-Hodgkin's lymphomas following combined B cell depletion therapy and CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone). Ann Rheum Dis. 2006;65:1033-1037.
84. Pollard RPE, Pijpe J, Bootsma H, et al. Treatment of mucosa-associated lymphoid tissue lymphoma in Sjogren's syndrome: A retrospective clinical study. J Rheumatol. 2011;38:2198-2208.
85. Meijer JM, Meiners PM, Vissink A, et al. Effectiveness of rituximab treatment in primary Sjogren's syndrome: A randomized, doubleblind, placebo-controlled trial. Arthritis Rheum. 2010;62:960-968.
86. Carubbi F, Cipriani P, Marrelli A, et al. Efficacy and safety of rituximab treatment in early primary Sjögren's syndrome: A prospective, multicenter, follow-up study. Arthritis Res Ther. 2013;15:R172.
87. Gottenberg J-E, Cinquetti G, Larroche C, et al. Efficacy of rituximab in systemic manifestations of primary Sjogren's syndrome: results in 78 patients of the AutoImmune and Rituximab registry. Ann Rheum Dis. 2013;72:1026-1031.
88. Seror R, Sordet C, Guillevin L, et al. Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjögren's syndrome. Ann Rheum Dis. 2007;66:351-357.
89. Dass S, Bowman SJ, Vital EM, et al. Reduction of fatigue in Sjogren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study. Ann Rheum Dis. 2008;67:1541-1544.
90. Moerman RV, Arends S, Meiners PM, et al. EULAR Sjogren's Syndrome Disease Activity Index (ESSDAI) is sensitive to show efficacy of rituximab treatment in a randomised controlled trial. Ann Rheum Dis. 2014;73:472-474.
91. Meiners PM, Arends S, Brouwer E, et al. Responsiveness of disease activity indices ESSPRI and ESSDAI in patients with primary Sjögren's syndrome treated with rituximab. Ann Rheum Dis. 2012;71:1297-1302.
92. Ramos-Casals M, García-Hernández FJ, de Ramón E, et al. Off-label use of rituximab in 196 patients with severe, refractory systemic autoimmune diseases. Clin Exp Rheumatol. 2010;28:468-476.
93. Bowman S, Everett C, Bombardieri M, et al. Preliminary results of a double-blind randomised trial of rituximab anti-B-cell therapy in patients with primary Sjogrens syndrome [abstract]. Arthritis Rheumatol (Hoboken, NJ). 2015;67:suppl 10. http://acrabstracts.org/abstract/preliminary-results-of-A-double-blind-randomised-trial-ofrituximab-anti-b-cell-therapy-in-patients-with-primary-sjogrenssyndrome/
94. Devauchelle-Pensec V, Mariette X, Jousse-Joulin S, et al. Treatment of primary Sjögren syndrome with rituximab: A randomized trial. Ann Intern Med. 2014;160:233-242.
95. Pijpe J, van Imhoff GW, Spijkervet FKL, et al. Rituximab treatment in patients with primary Sjögren's syndrome: an open-label phase II study. Arthritis Rheum. 2005;52:2740-2750.
96. Meijer JM, Pijpe J, Vissink A, et al. Treatment of primary Sjogren syndrome with rituximab: extended follow-up, safety and efficacy of retreatment. Ann Rheum Dis. 2009;68:284-285.
97. Devauchelle-Pensec V, Pennec Y, Morvan J, et al. Improvement of Sjögren's syndrome after two infusions of rituximab (anti-CD20). Arthritis Rheum. 2007;57:310-317.
98. St Clair EW, Levesque MC, Prak ETL, et al. Rituximab therapy for primary Sjögren's syndrome: an open-label clinical trial and mechanistic analysis. Arthritis Rheum. 2013;65:1097-1106.
99. Pijpe J, Meijer JM, Bootsma H, et al. Clinical and histologic evidence of salivary gland restoration supports the efficacy of rituximab treatment in Sjogren's syndrome. Arthritis Rheum. 2009;60:3251-3256.
100. Gottenberg J-E, Guillevin L, Lambotte O, et al. Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheum Dis. 2005;64:913-920.
101. Singh JA, Wells GA, Christensen R, et al. Adverse effects of biologics: A network meta-analysis and Cochrane overview. Cochrane Database Syst Rev. 2011;(2):CD008794. http://www.ncbi.nlm.nih.gov/pubmed/21328309
102. Terrier B, Amoura Z, Ravaud P, et al. Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry. Arthritis Rheum. 2010;62:2458-2466.
103. Carson KR, Focosi D, Major EO, et al. Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: A review from the Research on Adverse Drug Events and Reports (RADAR) Project. Lancet Oncol. 2009;10:816-824.
104. Hayashi Y, Kimura A, Kato S, et al. Progressive multifocal leukoencephalopathy and CD4+ T-lymphocytopenia in a patient with Sjögren syndrome. J Neurol Sci. 2008;268:195-198.
105. Hua C, Barnetche T, Combe B, et al. Effect of methotrexate, antitumor necrosis factor α, and rituximab on the immune response to influenza and pneumococcal vaccines in patients with rheumatoid arthritis: A systematic review and meta-analysis. Arthritis Care Res (Hoboken). 2014;66:1016-1026.
106. Steinfeld SD, Tant L, Burmester GR, et al. Epratuzumab (humanised anti-CD22 antibody) in primary Sjogren's syndrome: an open-label phase I/II study. Arthritis Res Ther. 2006;8:R129.
107. Wallace DJ, Kalunian K, Petri MA, et al. Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study. Ann Rheum Dis. 2014;73:183-190.
108. Furie R, Petri M, Zamani O, et al. A phase III, randomized, placebocontrolled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 2011;63:3918-3930.
109. Navarra SV, Guzman RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: A randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377:721-731.
110. Ginzler EM, Wallace DJ, Merrill JT, et al. Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus. J Rheumatol. 2014;41:300-309.
111. Mariette X, Seror R, Quartuccio L, et al. Efficacy and safety of belimumab in primary Sjogren's syndrome: results of the BELISS openlabel phase II study. Ann Rheum Dis. 2015;74:526-531.
112. Wallace DJ, Navarra S, Petri MA, et al. Safety profile of belimumab: pooled data from placebo-controlled phase 2 and 3 studies in patients with systemic lupus erythematosus. Lupus. 2013;22:144-154.
113. De Vita S, Quartuccio L, Seror R, et al. Efficacy and safety of belimumab given for 12 months in primary Sjögren's syndrome: The BELISS open-label phase II study. Rheumatology (Oxford). 2015;54:2249-2256.
114. Atzeni F, Sarzi-Puttini P, Mutti A, et al. Long-term safety of abatacept in patients with rheumatoid arthritis. Autoimmun Rev. 2013;12:1115-1117.
115. Keystone E, Alkhalaf A, Makkawy M. Subcutaneous abatacept in rheumatoid arthritis: current update. Expert Opin Biol Ther. 2015;15:1221-1230.
116. Meiners PM, Vissink A, Kroese FGM, et al. Abatacept treatment reduces disease activity in early primary Sjogren's syndrome (open-label proof of concept ASAP study). Ann Rheum Dis. 2014;73:1-4.
117. Adler S, Körner M, Förger F, et al. Evaluation of histological, serological and clinical changes in response to abatacept treatment of primary Sjögren's syndrome: A pilot study. Arthritis Care Res (Hoboken). 2013;65:1862-1868.
118. Mertens M, Singh JA. Anakinra for rheumatoid arthritis: A systematic review. J Rheumatol. 2009;36:1118-1125.
119. Norheim KB, Harboe E, Goransson LG, et al. Interleukin-1 inhibition and fatigue in primary Sjogren's syndrome-A double blind, randomised clinical trial. PLoS One. 2012;7:e30123.
120. Cavalli G, Dinarello CA. Treating rheumatological diseases and comorbidities with interleukin-1 blocking therapies. Rheumatology (Oxford). 2015;54:2134-2144.
121. Sakthiswary R, D'Cruz D. Intravenous immunoglobulin in the therapeutic armamentarium of systemic lupus erythematosus: A systematic review and meta-analysis. Medicine (Baltimore). 2014;93: e86.
122. Orbach H, Katz U, Sherer Y, et al. Intravenous immunoglobulin: adverse effects and safe administration. Clin Rev Allergy Immunol. 2005;29:173-184.
123. Rist S, Sellam J, Hachulla E, et al. Experience of intravenous immunoglobulin therapy in neuropathy associated with primary Sjögren's syndrome: A national multicentric retrospective study. Arthritis Care Res (Hoboken). 2011;63:1339-1344.
124. Choung B-S, Yoo W-H. Successful treatment with intravenous immunoglobulin of severe thrombocytopenia complicated in primary Sjögren's syndrome. Rheumatol Int. 2012;32:1353-1355.
125. David AL, Ataullah I, Yates R, et al. Congenital fetal heart block: A potential therapeutic role for intravenous immunoglobulin. Obstet Gynecol. 2010;116 Suppl:543-547.
126. Ii Y, Shindo A, Sasaki R, et al. Reversible stenosis of large cerebral arteries in a patient with combined Sjögren's syndrome and neuromyelitis optica spectrum disorder. Rheumatol Int. 2008;28:1277-1280.
127. Bienkowska J, Allaire N, Thai A, et al. Lymphotoxin-LIGHT pathway regulates the interferon signature in rheumatoid arthritis. PLoS One. 2014;9:e112545.
128. St. Clair W, Baer AN, Noaiseh G, et al. The clinical efficacy and safety of baminercept, a lymphotoxin-beta receptor fusion protein, in primary Sjögren's syndrome: results from a randomized, double-blind, placebo-controlled phase II trial [abstract]. Arthritis Rheumatol. 2015;67(suppl 10). http://acrabstracts.org/abstract/the-clinical-effi cacy-and-safety-of-baminercept-A-lymphotoxin-beta-receptorfusion-protein-in-primary-sjogrens-syndrome-results-from-A-rando mized-double-blind-placebo-controlled-phase-ii-trial/
129. Sankar V, Brennan MT, Kok MR, et al. Etanercept in Sjogren's syndrome: A twelve-week randomized, double-blind, placebo-controlled pilot clinical trial. Arthritis Rheum. 2004;50:2240-2245.
130. Mariette X, Ravaud P, Steinfeld S, et al. Inefficacy of infliximab in primary Sjogren's syndrome: results of the randomized, controlled trial of remicade in primary Sjogren's syndrome (TRIPSS). Arthritis Rheum. 2004;50:1270-1276.
131. Mavragani CP, Niewold TB, Moutsopoulos NM, et al. Augmented interferon-alpha pathway activation in patients with Sjögren's syndrome treated with etanercept. Arthritis Rheum. 2007;56:3995-4004.
132. Ioannidis JPA, Evans SJW, Gøtzsche PC, et al. Better reporting of harms in randomized trials: an extension of the CONSORT statement. Ann Intern Med. 2004;141:781-788.